Biocon Limited has informed the Exchange about Investor Presentation
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon reported Q3 FY26 revenue of ₹4,290 Cr, up 11% year-on-year, driven by a 24% jump in Generics and 9% growth in Biosimilars. Core EBITDA rose 21% YoY to ₹1,221 Cr with margins expanding from 26% to 29%, and reported net profit surged 475% YoY to ₹144 Cr. Biosimilars delivered strong margins of 28% (up from 21% YoY) led by Yesintek's market-leading position and oncology growth in North America. Management highlighted that major capex is largely behind and operating leverage is now kicking in, positioning the company for sustainable growth, margin expansion and improved cashflows. CRDMO was a soft spot, with revenue down 3% YoY due to issues at one manufacturing customer, though the BMS partnership was extended to 2035.
Positive for shareholders — broad-based margin expansion, strong biosimilars momentum and balance sheet improvement reinforce Biocon's pivot to a unified global biopharma platform. The CRDMO softness and biosimilars QoQ dip may limit upside in the near term, but the overall margin and profit trajectory is encouraging.